From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC
Autor: | Sai-Hong Ignatius Ou, Alexandria T.M. Lee, Misako Nagasaka |
---|---|
Rok vydání: | 2023 |
Předmět: | |
Zdroj: | Critical Reviews in Oncology/Hematology. 187:104019 |
ISSN: | 1040-8428 |
Databáze: | OpenAIRE |
Externí odkaz: |